R E S E A R C H A R T I C L E
Open Access
Impact of a nurse-based intervention on
medication outcomes in vulnerable older
adults
Michael A. Steinman
1,2,3,4*, Marcelo Low
3,4, Ran D. Balicer
3and Efrat Shadmi
3,4Abstract
Background:Medication-related problems are common in older adults with multiple chronic conditions. We
evaluated the impact of a nurse-based primary care intervention, based on the Guided Care model of care, on patient-centered aspects of medication use.
Methods:Controlled clinical trial of the Comprehensive Care for Multimorbid Adults Project (CC-MAP), conducted among 1218 participants in 7 intervention clinics and 6 control (usual care) clinics. Inclusion criteria included age 45–94, presence of≥3 chronic conditions, and Adjusted Clinical Groups (ACG) score > 0.19. The co-primary outcomes were number of changes to the medication regimen between baseline and 9 month followup, and number of changes to symptom-focused medications, markers of attentiveness to medication-related issues.
Results:Mean age in the intervention group was 72 years, 59% were women, and participants used a mean of 6.6
medications at baseline. The control group was slightly older (73 years) and used more medications (mean 7.1). Between baseline and 9 months, intervention subjects had more changes to their medication regimen than control subjects (mean 4.04 vs. 3.62 medication changes; adjusted difference 0.55,p= 0.001). Similarly, intervention subjects had more changes to their symptomatic medications (mean 1.38 vs. 1.26 changes, adjusted difference 0.20,p= 0.003). The total number of medications in use remained stable between baseline and follow-up in both groups (p> 0.18). Conclusion:This nurse-based, primary care intervention resulted in substantially more changes to patients’medication regimens than usual care, without increasing the total number of medications used. This enhanced rate of change likely reflects greater attentiveness to the medication-related needs of patients.
Trial registration:This trial is registered athttps://clinicaltrials.gov, trial numberNCT01811173.
Keywords:Polypharmacy, Medication management, Primary care, Israel, Aged, Multimorbidity, Quality of care
Background
Prescribing for older adults with multiple chronic condi-tions often leads to medication regimens that are overly complicated, difficult to adhere to, and contain multiple drug-drug and drug-disease interactions [1,2]. In addition, prescribing decisions often do not attend to patient
preferences, abilities, and goals of care [3]. This leaves patients feeling sidelined and disengaged from their care, with medication regimens that are not tailored to their needs and preferences [4].
Addressing these patient-centered issues requires patient-centered approaches to improving medication use. Such strategies use an understanding of patients’ needs and abilities to inform treatment decisions [5]. In addition, these strategies can help patients adhere to and properly use medications to maximally benefit their health and achieve their goals [6]. Yet, this is easier said than done. Programs such as patient-centered medical homes are promising but have shown mixed results, and * Correspondence:[email protected]
Prior presentation: 6thInternational Jerusalem Conference on Health Policy,
Jerusalem, Israel, May 2016; International Association of Geriatrics and Gerontology quadrennial meeting, San Francisco, CA, USA, July 2017.
1
University of California, 3333 California St, San Francisco, CA 94118, USA
2San Francisco VA Health Care System, 4150 Clement St, Box 181G, San
Francisco, CA 94121, USA
Full list of author information is available at the end of the article
there are few models of care that consistently achieve these ends and are practical for widespread use [7].
In recent years, a promising new model called Guided Care has been proposed that is well suited to address these needs [8]. Guided Care is a system of comprehen-sive, interdisciplinary care that is tailored to the needs of older adults with multiple chronic conditions [9]. In this model, a registered nurse based in a primary care clinic works with a panel of vulnerable older patients. The nurse interfaces with these patients via home visits, over the telephone, and in the clinic. These interactions include elements of case management, support for pa-tient self-management, and help with transitions of care. The nurse also works with patients’ clinicians to help coordinate care and bring patients’ needs, abilities, and preferences to clinical decision-making. Although it was not designed specifically to improve medication use, and does not incorporate any structured elements that focus explicitly on medications (such as medica-tion review or reconciliamedica-tion), its philosophy and pro-cesses are tightly aligned with the pharmaceutical care needs of older adults [10].
Previous studies have evaluated the impact of Guided Care on several outcomes such as mortality, mental and physical health, and caregiver burden [11–16]. However, little work has been done on how Guided Care impacts medication use and outcomes in vulnerable older adults. To fill this important evidence gap, we evaluated the effect of an intervention based on the Guided Care model on several aspects of medication prescribing for older adults in Israel. We hypothesized that older adults receiving this intervention would have improved markers of patient-centered prescribing – namely, more changes to their overall medication regimens, and more changes to their symptom-focused medications, representing greater attentiveness to adjusting medication regimens in re-sponse to patient symptoms, challenges with existing medications, and goals of care.
Methods
Intervention and study population
This study uses data from the Comprehensive Care for Multimorbid Adults Project (CC-MAP), a controlled clinical trial of a nurse-based intervention that was con-ducted within primary care clinics of Clalit Health Sys-tems [17]. Clalit is Israel’s largest integrated health care provider and insurer, serving approximately half the country’s population.
In the CC-MAP study, representative (but not ran-domized) primary care clinics within 2 regions of Israel were selected as intervention and control sites. In the 7 intervention sites, nurses trained in the CC-MAP model were embedded in a clinic, which typically comprised 3 to 4 physicians plus support staff. CC-MAP nurses
followed a panel of vulnerable adults who met the inclu-sion/exclusion criteria outlined below. Six control clinics were selected with similar demographic and health system characteristics as the intervention clinics. In the control clinics, patients received usual care.
Intervention patients met with the CC-MAP nurse monthly in person or by phone, and in person at least once per quarter, to review their care plan, make adjust-ments and receive counseling as needed, and follow up. When a patient was hospitalized, the CC-MAP nurse contacted the patient immediately after discharge to review changes in treatment recommendations, and as needed alert the primary care physician to implement treatment changes described in discharge recommenda-tions. As this complex intervention was tailored to the needs and preferences of each participant, some subjects received more intensive services and contacts than others, although all intervention subjects enrolled had a minimum of 3 contacts (in person or by telephone) with CC-MAP nurses per year, with most having substantially more. There was no specific medication reconciliation or pharmacy component to the intervention, although since the nurse was part of a nurse-primary care phys-ician team, part of her role was to periodically assess the patient’s status, including adherence to the care plan. Thus, when the nurse identified that the patient had side effects from medications, or that he/she was not adher-ing to the treatment, she notified the primary care phys-ician. This provided an opportunity to be able to tailor care to patients’evolving status and needs.
Inclusion criteria included community-dwelling adults age 45–94 years and the presence of 3 or more chronic conditions. In addition, we employed a Johns Hopkins Adjusted Clinical Group® (ACG) system predictive mod-eling score using diagnosis and pharmacy data (the DxRxPM model), restricting enrollment to people with a score > 0.19, indicating high risk of poor clin-ical outcomes [18]. Exclusion criteria included inabil-ity to speak Hebrew or Russian, current participation in a disease management program, use of dialysis or chemotherapy, advanced dementia, or severe mental illness such as schizophrenia (see Fig. 1). Over 70% of the study population was age 65 and older. Interven-tion subjects were enrolled between April 2013 and June 2014, and control subjects between November 2013 and March 2015.
Measures
listed below. We chose these outcomes based on domains where we hypothesized the CC-MAP intervention could have particularly beneficial impacts on medication use. We considered these 2 outcomes co-primary for purposes of this study.
Medication use was assessed using pharmacy dispens-ing data from Clalit pharmacies and from non-Clalit pharmacies where Clalit insurance was billed. To-gether these account for the strong majority of pre-scription medications filled by Clalit members, who have powerful financial incentives to fill their medica-tions using their Clalit benefits [19, 20]. We employed a variant of methods recommended by Lund et al. to identify prevalent medication use at time points of interest [21]. Because it can be difficult to ascertain dose and duration of medications that are delivered topic-ally or loctopic-ally, we restricted our analyses to medication
classes that are delivered systemically and/or have sys-temic effects.
Outcome #1 - Number of changes in medication regimen
dose changes (the same medication given at different daily doses at baseline vs. 9 months) [22].
Outcome #2–Change in use of symptom-focused medications
We hypothesized that improved communication about patient symptoms would lead to more fine-tuning of symptom-focused medications. Our co-primary outcome was the number of changes in symptom-focused medications between baseline and 9 months. A sec-ondary outcome was the total number of symptom-focused medications in use at 9 months. Methods for defining symptom-focused medications are de-scribed in Additional file 1: Appendix S1.
Other variables
Patient demographics were collected from Clalit data systems. Comorbid conditions were assessed using algo-rithms developed for Clalit clinical and claims data, for example using inpatient and outpatient diagnoses, phar-macy records, and laboratory test results. The unweighted sum of 27 chronic conditions defined a patient-level comorbidity score. ACG scores were calculated using clinical and claims data using standard methods employed by Clalit and validated for CC-MAP patient selection [23, 24]. Higher ACG scores predict a variety of poor clinical outcomes [24].
Main analyses
Our analyses used an intention to treat framework. Overall, 45 intervention subjects and 1 control subject withdrew from participation in the intervention and/or followup assessments between baseline and 9 months, and 3 intervention subjects moved to a different clinic. (The differential drop-out rate is likely explained by bur-den and/or dislike of the intervention by intervention subjects, whereas control subjects had only usual care.) Although these subjects withdrew from participation or moved, we were able to assess their medication out-comes as medication use was measured using pharmacy claims data, which were generated irrespective of trial participation. Thus, these subjects were included in the final analysis according to their original treatment assignment.
All analyses employed mixed effects regression, using random effects to adjust for clustering of study subjects within physicians, and fixed effects to adjust for region. Clinic-level random effects were negligible after account-ing for physician random effects. Outcomes analyses controlled for potential confounders including age, sex, comorbidity count, ACG DxRxPM score, number of medications present at baseline, and the number of medication changes that had occurred between 9 months before baseline and baseline (to account each subject’s
pre-baseline rate of medication changes). We used inter-action terms to evaluate potential effect modification among pre-specified subgroups defined by age, ACG predictive modeling score, and number of medications used at baseline.
The enrollment period for intervention subjects began and ended earlier than the enrollment period for control subjects, with only partial overlap. To evaluate if secular trends could have impacted our results, we assessed the impact of enrollment time on our medication out-comes in each treatment group. In these analyses, enrollment time was not associated with outcomes in either group (p> .15 for all).
Exploratory analyses
We conducted an exploratory analysis to understand the relationship between our primary outcome meas-ure (number of medication changes) and patient-cen-teredness. We hypothesized that a greater number of medication changes over time would be associated with greater patient-centeredness, reflecting increased attention to patients’ medication-related needs and challenges. This analysis used data from the Patient Assessment of Chronic Illness Care (PACIC) ques-tionnaire, which was completed by control subjects at baseline. (Accurate baseline data were not available for intervention subjects). Our predictor variable was the number of medication changes in the 9 months prior to the time the PACIC was administered. Our outcome variable was the sum of scores for the first 3 items on the PACIC questionnaire, which address the patient-centeredness of treatment planning, and which have been validated to have strong psychomet-ric properties (Cronbach’s alpha 0.82, standardized factor loadings > 0.75) [25]. Answers to these items were summed into a score ranging from 3 (never in-volved in treatment planning) to 15 (always inin-volved in treatment planning). We used Poisson regression to evaluate the predictor-outcome relationship, while controlling for potential confounders including num-ber of medications in the pre-baseline period, numnum-ber of chronic conditions, ACG predictive modeling score, age, race, and sex, and adjusting for clinician as a random effect (see Additional file1: Appendix S5).
This study adheres to CONSORT guidelines and was approved by the institutional review boards of Clalit Health Services and the University of California, San Francisco.
Results
received care in 7 intervention clinics by 21 primary care physicians. The 598 control patients received care in 6 control clinics predominantly by 17 primary care physicians.
Baseline characteristics of intervention control patients are shown in Table 1. Compared with control patients, intervention patients were slightly younger, had fewer chronic conditions, and received fewer medications.
Effect of CC-MAP intervention on changes in medication use
Between baseline and 9 months, intervention patients had a mean of 4.04 changes to their medication regimens (Table 2). Control patients had a mean of 3.62 changes. After adjusting for baseline characteristics, intervention patients had a mean of 0.55 more medication changes than control subjects (p= .001; see Additional file 1: Appendix S3 for additional information).
A similar pattern was observed for changes in the use of symptom-focused medications. Between base-line and 9 month followup, intervention patients had more changes to their regimen of symptom-focused medications than control patients (mean 1.38 vs. 1.27 changes, adjusted mean difference 0.20 changes,
p= .003).
As a sensitivity analysis, we expanded our definition of symptom-focused medications to include drugs used to treat intermittent but highly symptomatic conditions, and medications with mixed symptom-focused and non-symptom-focused uses. Results were similar using this expanded definition: intervention patients had more changes to the regimen of symptom-focused medications than control patients (mean 1.89 vs 1.81 changes, ad-justed mean difference 0.20 changes,p= .01).
Characteristics of medication changes
In both the intervention and control groups, there was little difference in the total number of medications subjects used at baseline and at 9 months. The interven-tion group used a mean of 0.09 more medicainterven-tions at 9 months compared with baseline (p= 0.32 for change). The control group used a mean of 0.12 fewer medica-tions at 9 months compared with baseline (p= 0.18 for change; p= .12 for difference in change between inter-vention and control groups).
The total number of symptom-focused medications also remained generally stable from baseline to 9 months, although there was a small, statistically significant increase in the intervention group. The intervention group used a mean of 0.13 more symptom-focused medications at 9 months compared with baseline (p= 0.02 for change). The control group used 0.03 fewer symptom-focused medications at 9 months (p= 0.59 for change;p= 0.06 for difference in number of changes be-tween groups).
The distribution of types of medication changes (e.g. additions, discontinuations, therapeutic substitutions, and dose changes) were generally similar across groups (Table 3). The distribution of which classes of drugs were changed was also similar in the two groups. The most commonly changed medication class was cardio-vascular medications, which accounted for 30% of changes in the intervention group and 29% in the con-trol group (p= 0.31 for difference; see Additional file 1: Appendix S4 for additional information).
Subgroup effects
The impact of the intervention on both medication change outcomes did not vary between patients of differ-ent age (under 75 vs. 75 or more years), ACG score
Table 1Baseline characteristics of intervention and control subjects
InterventionN= 622 ControlN= 596
Age (mean, SD) 71.6 (10.2) 73.4 (9.9)
Female sex 365 (59) 329 (55)
No. of chronic conditions (mean, SD)a 4.1 (2.1) 4.8 (2.3)
ACG score (median, IQR)b 0.29 (0.22–0.42) 0.25 (0.18–0.39)
Number of medications at baseline (mean, SD) 6.6 (3.3) 7.1 (3.2)
Number of changes in medications in the 9 months prior to baseline 3.9 (2.7) 3.9 (2.8)
Number of symptom-focused medications at baseline
0 203 (33) 150 (25)
1 161 (26) 165 (28)
2 or more 258 (41) 281 (47)
pvalue < 0.05 for difference between groups for age, number of chronic conditions, ACG score, and number of medications (overall and symptom-focused) at baseline
a
From a list of 27 chronic conditions b
(under 0.27 vs. 0.27 or greater), number of medications at baseline (under 7 vs 7 or more), and number of symptom-focused medications at baseline (0 to 1 vs. 2 or more), with p values for interaction > 0.37 in each comparison.
Exploratory analyses
In an exploratory analysis, we used data from the control group to evaluate the relationship between number of medication changes and the patient-centeredness of treatment planning. On a scale of 3–15 (with 15 being best), the median 3-item PACIC score was 6 (interquar-tile range, 3–9). There was a non-linear relationship between number of medication changes and 3-item PACIC scores. Compared to subjects with 0–2 medica-tion changes, 3-item PACIC scores were a mean of 0.30 points higher in subjects with 3–5 medication changes, but 0.44 points lower in subjects with 6 or more changes (p= 0.003 for difference in scores between categories). After controlling for several potential confounders, the differences remained (p= .03; see Additional file 1: Appendix S5 for details).
Discussion
In this controlled clinical trial, the CC-MAP interven-tion–a nurse based, primary care intervention based on the Guided Care model of care – improved several aspects of prescribing in vulnerable Israeli adults. Com-pared with usual care, patients receiving the CC-MAP intervention had more changes to their medication
regimens in general, and more changes in their symp-tom-focused medications. This increased rate of changes may reflect more attentive management to patients’ medication-related needs.
Our findings build on prior research on the Guided Care model of care. Past studies have shown that Guided Care improves patient-centered processes of care, in-cluding goal-setting, coordination of care, decision sup-port, and patient activation [11–14]. This study adds a new dimension to these findings by improving markers of patient-centered medication management. However, despite benefits in processes of care, a large trial of Guided Care did not demonstrate significantly beneficial effects on health outcomes including self-reported measures of physical and mental health, mortality, and several forms of health services utilization [15, 16]. Al-though these findings are disappointing, they are not the last word. The trial was underpowered to detect small but clinically meaningful differences in these outcomes, and provided lessons about potential future improve-ments in this care model [15,16]. Subsequent work test-ing refined models of Guided Care are underway, including the CC-MAP trial, which is showing promise for improving these hard outcomes.
One noteworthy aspect of our findings is that improv-ing medication use was not a primary goal of the inter-vention, and in fact the CC-MAP program had no structured elements that focused explicitly on medica-tions. Rather, the improved markers of medication use that we observed appear to be a beneficial “side effect” Table 2Number of medication changes between baseline and 9 months, intervention vs. control group
InterventionN= 622 ControlN= 596 Adjusted difference in number
of medication changesa pvalue
Total number of changes to medication regimen (mean, SD)
4.04 (2.8) 3.62 (2.7) 0.55 .001
Total number of changes of symptom-focused medications (mean, SD)
1.38 (1.5) 1.27 (1.5) 0.20 .003
a
Adjusted for baseline subject characteristics and clustering
Table 3Types of medication changes between baseline and 9 months, intervention vs. control group
Types of medication change Intervention N= 622
Mean # of changes (% of total)a
Control N= 596
Mean # of changes (% of total)a
Adjusted differenceb pvalue
Medication additions 1.79 (44%) 1.51 (42%) 2% 0.37
Medication discontinuations 1.70 (42%) 1.63 (45%) 3% 0.09
Therapeutic substitutions 0.15 (4%) 0.15 (4%) 0% 0.91
Dose increases 0.18 (5%) 0.19 (6%) 1% 0.39
Dose reductions 0.21 (6%) 0.15 (4%) 2% 0.007
TOTAL NUMBER OF CHANGES 4.04 (100%) 3.62 (100%) – –
a
Results show the mean number of each type of medication change within each group, and the percent of all changes attributable to each type of change b
of the more general goals of the CC-MAP program such as improving communication and care coordination. Vulnerable older adults require support in many areas, for example improving pharmacotherapy, assessing and maintaining functional and cognitive abilities, and much more [26]. Yet, it is impractical to offer multiple discrete interventions, each targeted to only one area [27]. In being able to improve a domain of care that was not an explicit focus of the intervention, CC-MAP and Guided Care show promise as a single intervention which that can favorably affect multiple domains.
The first two measures of prescribing that we evalu-ated – the number of changes in medications overall, and the number of changes in symptom-focused medica-tions–are not standard measures of prescribing quality, and have not been validated as markers of this construct. Thus, we cannot be sure that the higher number of changes observed in the intervention group represents better care. Our analyses between number of medication changes and treatment-planning components of the PACIC score suggest there may be a threshold effect: a moderate number of changes are associated with more patient-centered care, but a large volume of changes has the opposite effect. However, this finding should be con-sidered preliminary, since it used only a subset of the PACIC score and was unable to control for potentially important confounders.
Although these caveats are important, these markers nonetheless have potential to be valuable [22]. Many commonly used markers of prescribing quality, such as prescribing of drugs to avoid in older adults (e.g. the Beers and STOPP criteria) are not particularly patient-centered [28, 29]. What often matters most for patients is individualizing their medication regimen to suit their particular circumstance, yet studies have shown that clinical inertia and competing demands often prevent appropriate modification of regimens to meet changing patient needs [30–32]. Although more changes are not always better, in this context they may reflect more attention to individual patient cir-cumstances [33].
Additional findings also shed light on the meaning of the increased rate of medication changes observed in the intervention group. The total number of medications used by intervention subjects remained stable despite the higher number of medication changes. The interven-tion thus appears to have enhanced “fine-tuning” of medications rather than adding to the already-large numbers of medications used by study subjects. It is also noteworthy that the intervention did not preferentially affect one type of medication change or one class of medications. This appears to reflect a generalized ef-fect of the intervention rather than focused changes in one specific area.
Our study has several limitations. Due to practical considerations the selection of intervention and control clinics was not random. However, we were able to con-trol for multiple baseline characteristics of subjects, including their pre-baseline rate of medication changes, which substantially reduces potential for bias in our results. Medication use was ascertained using pharmacy dispensing records. As a result, our measures of medica-tion use are affected both by what medicamedica-tions the physician(s) ordered and patients’ adherence to obtain-ing those medications; we are unable to distobtain-inguish the relative contribution of each. Nonetheless, this does not affect our conclusions since both physician prescribing and patient adherence are important facets of medica-tion use that may be improved by the intervenmedica-tion. In addition, we were unable to account for medications not captured in Clalit databases. However, this likely ac-counts for only a small fraction of medications filled, given strong incentives to fill medications using Clalit insurance benefits, and is unlikely to differ between intervention and control subjects. Finally, we did not evaluate the impact of the intervention on clinical outcomes such as medication errors, hospitalizations, or symptom control; these will be important avenues for future research.
Conclusions
The CC-MAP intervention, a nurse-based primary care program based on the Guided Care model of care, improved markers of patient-centered prescribing in vulnerable adults. With further attention to medication-related issues, this program – which had little explicit focus on medication use – might further improve pre-scribing and improve medication-related outcomes in vulnerable older adults.
Additional file
Additional file 1:Appendix S1.Defining symptom-focused medica-tions–introduction.Appendix S2.Defining symptom-focused medica-tions–drug class coding.Appendix S3.Full multivariable model comparing medication change outcomes in intervention and control subjects.Appendix S4.Distribution of medication classes used at base-line, and of medication classes that were changed between baseline and 9 months.Appendix S5.Relationship between number of medication changes and patient-centeredness of treatment planning (3-item PACIC score), in control group. (DOCX 53 kb)
Abbreviations
ACG:Adjusted Clinical Group; CC-MAP: Comprehensive Care for Multimorbid Adults Project; PACIC: Patient Assessment of Chronic Illness Care
Acknowledgements
Funding
This work was supported by the Gertner Institute, Clalit Health Services, and by the University of California San Francisco Research Allocation Program. The sponsors had no role in the study design, methods, subject recruitment, data collection, analysis, preparation of manuscripts, or the decision to publish.
Availability of data and materials
The datasets generated and/or analysed during the current study are not publicly available due to threats to subject privacy but are available from the corresponding author on reasonable request.
Authors’contributions
Study concept and design: MAS, ML, RDB, ES. Subject recruitment and data collection: RDB, ES. Analysis and interpretation of data: MAS, ML, RDB, ES. Drafting of initial version of the manuscript: MAS. Review of manuscript for critical intellectual content: ML, RDB, ES. All authors read and approved the final manuscript.
Ethics approval and consent to participate
This study was approved by the institutional review boards of Clalit Health Services and the University of California, San Francisco. All subjects provided written informed consent to participate in the study.
Consent for publication Not applicable.
Competing interests
Dr. Steinman has served as a consultant foriodine.com. Mr. Low and Drs Balicer and Shadmi report no conflicts.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Author details 1
University of California, 3333 California St, San Francisco, CA 94118, USA.
2San Francisco VA Health Care System, 4150 Clement St, Box 181G, San
Francisco, CA 94121, USA.3Clalit Research Institute, Tel Aviv, Israel.4University of Haifa, Haifa, Israel.
Received: 31 January 2018 Accepted: 29 August 2018
References
1. Steinman MA, Hanlon JT. Managing medications in clinically complex elders:“There’s got to be a happy medium”. JAMA. 2010;304(14):1592–601. 2. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;
353(5):487–97.
3. Boyd CM, Darer J, Boult C, Fried LP, Boult L, Wu AW. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA. 2005;294(6):716–24. 4. Fried TR, Tinetti ME, Iannone L, O'Leary JR, Towle V, Van Ness PH. Health
outcome prioritization as a tool for decision making among older persons with multiple chronic conditions. Arch Intern Med. 2011;171(20):1854–6. 5. McMullen CK, Safford MM, Bosworth HB, et al. Patient-centered priorities for
improving medication management and adherence. Patient Educ Couns. 2015;98(1):102–10.
6. Viswanathan M, Golin CE, Jones CD, Ashok M, Blalock SJ, Wines RC, Coker-Schwimmer EJ, Rosen DL, Sista P, Lohr KN. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med. 2012;157(11):785–95. 7. Jackson GL, Powers BJ, Chatterjee R, et al. Improving patient care. The
patient centered medical home. A systematic review. Ann Intern Med. 2013; 158(3):169–78.
8. Boyd CM, Boult C, Shadmi E, et al. Guided care for multimorbid older adults. Gerontologist. 2007;47(5):697–704.
9. Boult C, Reider L, Frey K, et al. Early effects of“guided care”on the quality of health care for multimorbid older persons: a cluster-randomized controlled trial. J Gerontol A Biol Sci Med Sci. 2008;63(3):321–7.
10. Kuntz JL, Safford MM, Singh JA, et al. Patient-centered interventions to improve medication management and adherence: a qualitative review of research findings. Patient Educ Couns. 2014;97(3):310–26.
11. Boyd CM, Reider L, Frey K, et al. The effects of guided care on the perceived quality of health care for multi-morbid older persons: 18-month outcomes from a cluster-randomized controlled trial. J Gen Intern Med. 2010;25(3): 235–42.
12. Wolff JL, Giovannetti ER, Boyd CM, et al. Effects of guided care on family caregivers. Gerontologist. 2010;50(4):459–70.
13. Marsteller JA, Hsu YJ, Reider L, et al. Physician satisfaction with chronic care processes: a cluster-randomized trial of guided care. Ann Fam Med. 2010; 8(4):308–15.
14. Marsteller JA, Hsu YJ, Wen M, et al. Effects of guided care on providers’ satisfaction with care: a three-year matched-pair cluster-randomized trial. Popul Health Manag. 2013;16(5):317–25.
15. Boult C, Reider L, Leff B, et al. The effect of guided care teams on the use of health services: results from a cluster-randomized controlled trial. Arch Intern Med. 2011;171(5):460–6.
16. Boult C, Leff B, Boyd CM, et al. A matched-pair cluster-randomized trial of guided care for high-risk older patients. J Gen Intern Med. 2013;28(5): 612–21.
17. Clalit Research Institute: Multimorbidity Care Management (CC-MAP).http:// clalitresearch.org/research-areas/areas/multimorbidity/.
Accessed 29 May 2016.
18. Forrest CB, Lemke KW, Bodycombe DP, Weiner JP. Medication, diagnostic, and cost information as predictors of high-risk patients in need of care management. Am J Manag Care. 2009;15(1):41–8.
19. Singer SR, Hoshen M, Shadmi E, et al. EMR-based medication adherence metric markedly enhances identification of nonadherent patients. Am J Manag Care. 2012;18(10):e372–7.
20. Marom O, Rennert G, Stein N, Landsman K, Pillar G. Characteristics and trends in hypnotics consumption in the largest health care system in Israel. Sleep Disord. 2016;2016:8032528.
21. Lund BC, Chrischilles EA, Carter BL, Ernst ME, Perry PJ. Development of a computer algorithm for defining an active drug list using an automated pharmacy database. J Clin Epidemiol. 2003;56(8):802–6.
22. Lam KD, Miao Y, Steinman MA. Cumulative changes in the use of long-term medications: a measure of prescribing complexity. JAMA Intern Med. 2013; 173(16):1546–7.
23. Cohen CJ, Flaks-Manov N, Low M, Balicer RD, Shadmi E. High-risk case identification for use in comprehensive complex care management. Popul Health Manag. 2015;18(1):15–22.
24. Shadmi E, Balicer RD, Kinder K, Abrams C, Weiner JP. Assessing socioeconomic health care utilization inequity in Israel: impact of alternative approaches to morbidity adjustment. BMC Public Health. 2011;11:609.
25. Glasgow RE, Wagner EH, Schaefer J, Mahoney LD, Reid RJ, Greene SM. Development and validation of the patient assessment of chronic illness care (PACIC). Med Care. 2005;43(5):436–44.
26. Wenger NS, Shekelle PG. Assessing care of vulnerable elders: ACOVE project overview. Ann Intern Med. 2001;135(8 Pt 2):642–6.
27. Boult C, Green AF, Boult LB, Pacala JT, Snyder C, Leff B. Successful models of comprehensive care for older adults with chronic conditions: evidence for the Institute of Medicine's“retooling for an aging America”report. J Am Geriatr Soc. 2009;57(12):2328–37.
28. American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2015 updated beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2015; 63(11):2227–46.
29. Gallagher P, Ryan C, Byrne S, Kennedy J, O'Mahony D. STOPP (screening tool of older Person’s prescriptions) and START (screening tool to alert doctors to right treatment). Consensus validation. Int J Clin Pharmacol Ther. 2008;46(2):72–83.
30. Kerr EA, Lucatorto MA, Holleman R, Hogan MM, Klamerus ML, Hofer TP. Monitoring performance for blood pressure management among patients with diabetes mellitus: too much of a good thing? Arch Intern Med. 2012; 172(12):938–45.
32. Steinman MA, Patil S, Kamat P, Peterson C, Knight SJ. A taxonomy of reasons for not prescribing guideline-recommended medications for patients with heart failure. Am J Geriatr Pharmacother. 2010;8(6):583–94. 33. Yam FK, Lew T, Eraly SA, Lin HW, Hirsch JD, Devor M. Changes in
